Related Experiment Video
Updated: Oct 10, 2025
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
[Transcriptome Analysis of Chronic Myelogenous Leukemia Cell Line with Imatinib Resistance]
Xiao Han1, Zhi-Kui Deng2, Cheng-Wan Zhang1
1Department of Central Laboratory, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an 223300, Jiangsu Province, China.
Objective:
To investigate the regulation of chronic myelogenous leukemia （CML） imatinib resistant genes, in order to improve the therapeutic effect of CML imatinib resistant patients.
Methods:
The human CML cell line K562 and imatinib-resistant K562 cells (K562/G01) were collected, and transcriptome of the cells were achieved by RNA-seq. The sequencing data were analyzed by using standard procedures.
Results:
Compared with K562 cells, 464 genes were significantly changed in K562/G01 cells, including 163 up-regulated and 301 down-regulated genes. The GO function annotation analysis and KEGG pathway analysis results showed that the differentially expressed genes were mainly involved in biological processes such as oxidative phosphorylation, localization to protein organelle, ribonucleoprotein complex biogenesis and so on. Gene Set Enrichment Analysis (GSEA) plots showed that 5 gene-sets were up-regulated in K562/G01 significantly, including the pathway of TGF-beta, mTOR and CML.
Conclusion:
CML imatinib resistance is associated with oxidative phosphorylation, during which the pathway of TGF-beta and mTOR are significantly up-regulated.
Insights
Chronic myelogenous leukemia (CML) imatinib resistance involves altered gene expression, particularly in oxidative phosphorylation pathways like TGF-beta and mTOR. Understanding these changes can improve CML treatment outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Chronic myelogenous leukemia (CML) is a hematologic malignancy.
- Imatinib is a targeted therapy for CML, but resistance can develop.
- Understanding the molecular mechanisms of imatinib resistance is crucial for improving patient outcomes.
Purpose of the Study:
- To investigate the gene expression changes associated with imatinib resistance in CML.
- To identify key biological pathways involved in CML imatinib resistance.
- To provide insights for enhancing therapeutic strategies for imatinib-resistant CML patients.
Main Methods:
- Utilized RNA sequencing (RNA-seq) to analyze the transcriptome of K562 (CML cell line) and K562/G01 (imatinib-resistant CML cell line) cells.
- Performed standard bioinformatics analyses, including Gene Ontology (GO) function annotation and KEGG pathway analysis.
- Employed Gene Set Enrichment Analysis (GSEA) to identify significantly altered gene sets and pathways.
Main Results:
- Identified 464 significantly differentially expressed genes between K562 and K562/G01 cells (163 up-regulated, 301 down-regulated).
- Differentially expressed genes were primarily associated with oxidative phosphorylation, protein localization, and ribonucleoprotein complex biogenesis.
- Gene Set Enrichment Analysis revealed significant up-regulation of TGF-beta, mTOR, and CML pathways in imatinib-resistant cells.
Conclusions:
- CML imatinib resistance is linked to alterations in oxidative phosphorylation.
- The TGF-beta and mTOR signaling pathways are significantly up-regulated in the context of CML imatinib resistance.
- These findings suggest potential therapeutic targets for overcoming imatinib resistance in CML.
